epcam靶向厄洛替尼递送：聚乙二醇包覆氧化石墨烯增强鼻咽癌治疗

IF 2.3 3区医学 Q1 OTORHINOLARYNGOLOGY

Head and Neck-Journal for the Sciences and Specialties of the Head and Neck Pub Date : 2025-02-27 DOI:10.1002/hed.28122

Chien-Fu Yeh, Sheng-Wei Lee, Chin-Hsuan Liu, Yen-Bin Hsu, Ming-Chin Lan, Yu-Jen Lu, Jyh-Ping Chen, Ming-Ying Lan

{"title":"epcam靶向厄洛替尼递送：聚乙二醇包覆氧化石墨烯增强鼻咽癌治疗","authors":"Chien-Fu Yeh, Sheng-Wei Lee, Chin-Hsuan Liu, Yen-Bin Hsu, Ming-Chin Lan, Yu-Jen Lu, Jyh-Ping Chen, Ming-Ying Lan","doi":"10.1002/hed.28122","DOIUrl":null,"url":null,"abstract":"Background: Recently, graphene oxide (GO) has attracted significant attention as a potential innovative vehicle for the delivery of anticancer agents. In this study, we aimed to evaluate whether functionalized GO, known as epithelial cell adhesion molecule (EpCAM)-targeted polyethylene glycol (PEG)-coated GO (GO-PEG-EpCAM), could be used as a therapeutic agent against nasopharyngeal carcinoma (NPC) and to identify its underlying molecular mechanisms.Methods: We used NPC cells to assess the anticancer effects of GO-PEG-EpCAM/erlotinib in vitro and in vivo. Employing RNA sequencing and Ingenuity Pathway Analysis (IPA), we sought to elucidate the molecular pathways through which GO-PEG-EpCAM/erlotinib affects NPC cells.Results: Our findings revealed that GO-PEG-EpCAM/erlotinib reduced NPC cell viability and decreased invasion and migration abilities. An in vivo study further corroborated the anticancer potential of GO-PEG-EpCAM/erlotinib. Our comprehensive RNA sequencing analysis highlighted several molecular mechanisms underlying the anticancer effects of GO-PEG-EpCAM/erlotinib.Conclusions: GO-PEG-EpCAM/erlotinib could be a potential therapeutic strategy for NPC.","PeriodicalId":55072,"journal":{"name":"Head and Neck-Journal for the Sciences and Specialties of the Head and Neck","volume":" ","pages":""},"PeriodicalIF":2.3000,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"EpCAM-Targeted Erlotinib Delivery: Enhancing Nasopharyngeal Carcinoma Treatment With Polyethylene Glycol-Coated Graphene Oxide.\",\"authors\":\"Chien-Fu Yeh, Sheng-Wei Lee, Chin-Hsuan Liu, Yen-Bin Hsu, Ming-Chin Lan, Yu-Jen Lu, Jyh-Ping Chen, Ming-Ying Lan\",\"doi\":\"10.1002/hed.28122\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background: Recently, graphene oxide (GO) has attracted significant attention as a potential innovative vehicle for the delivery of anticancer agents. In this study, we aimed to evaluate whether functionalized GO, known as epithelial cell adhesion molecule (EpCAM)-targeted polyethylene glycol (PEG)-coated GO (GO-PEG-EpCAM), could be used as a therapeutic agent against nasopharyngeal carcinoma (NPC) and to identify its underlying molecular mechanisms.Methods: We used NPC cells to assess the anticancer effects of GO-PEG-EpCAM/erlotinib in vitro and in vivo. Employing RNA sequencing and Ingenuity Pathway Analysis (IPA), we sought to elucidate the molecular pathways through which GO-PEG-EpCAM/erlotinib affects NPC cells.Results: Our findings revealed that GO-PEG-EpCAM/erlotinib reduced NPC cell viability and decreased invasion and migration abilities. An in vivo study further corroborated the anticancer potential of GO-PEG-EpCAM/erlotinib. Our comprehensive RNA sequencing analysis highlighted several molecular mechanisms underlying the anticancer effects of GO-PEG-EpCAM/erlotinib.Conclusions: GO-PEG-EpCAM/erlotinib could be a potential therapeutic strategy for NPC.\",\"PeriodicalId\":55072,\"journal\":{\"name\":\"Head and Neck-Journal for the Sciences and Specialties of the Head and Neck\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":2.3000,\"publicationDate\":\"2025-02-27\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Head and Neck-Journal for the Sciences and Specialties of the Head and Neck\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1002/hed.28122\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"OTORHINOLARYNGOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Head and Neck-Journal for the Sciences and Specialties of the Head and Neck","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/hed.28122","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OTORHINOLARYNGOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

背景：最近，氧化石墨烯（GO）作为一种潜在的抗癌药物递送创新载体引起了人们的极大关注。在这项研究中，我们旨在评估功能化氧化石墨烯，即上皮细胞粘附分子（EpCAM）靶向聚乙二醇（PEG）包被氧化石墨烯（GO-PEG-EpCAM），是否可以用作鼻咽癌（NPC）的治疗剂，并确定其潜在的分子机制。方法：采用鼻咽癌细胞，体外和体内评价GO-PEG-EpCAM/厄洛替尼的抗癌作用。利用RNA测序和匠心途径分析（Ingenuity Pathway Analysis， IPA），我们试图阐明GO-PEG-EpCAM/厄洛替尼影响鼻咽癌细胞的分子途径。结果：我们的研究结果显示，GO-PEG-EpCAM/厄洛替尼降低了鼻咽癌细胞的活力，降低了侵袭和迁移能力。一项体内研究进一步证实了GO-PEG-EpCAM/厄洛替尼的抗癌潜力。我们全面的RNA测序分析强调了GO-PEG-EpCAM/厄洛替尼抗癌作用的几个分子机制。结论：GO-PEG-EpCAM/厄洛替尼可能是鼻咽癌的潜在治疗策略。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

EpCAM-Targeted Erlotinib Delivery: Enhancing Nasopharyngeal Carcinoma Treatment With Polyethylene Glycol-Coated Graphene Oxide.

Background: Recently, graphene oxide (GO) has attracted significant attention as a potential innovative vehicle for the delivery of anticancer agents. In this study, we aimed to evaluate whether functionalized GO, known as epithelial cell adhesion molecule (EpCAM)-targeted polyethylene glycol (PEG)-coated GO (GO-PEG-EpCAM), could be used as a therapeutic agent against nasopharyngeal carcinoma (NPC) and to identify its underlying molecular mechanisms.

Methods: We used NPC cells to assess the anticancer effects of GO-PEG-EpCAM/erlotinib in vitro and in vivo. Employing RNA sequencing and Ingenuity Pathway Analysis (IPA), we sought to elucidate the molecular pathways through which GO-PEG-EpCAM/erlotinib affects NPC cells.

Results: Our findings revealed that GO-PEG-EpCAM/erlotinib reduced NPC cell viability and decreased invasion and migration abilities. An in vivo study further corroborated the anticancer potential of GO-PEG-EpCAM/erlotinib. Our comprehensive RNA sequencing analysis highlighted several molecular mechanisms underlying the anticancer effects of GO-PEG-EpCAM/erlotinib.

Conclusions: GO-PEG-EpCAM/erlotinib could be a potential therapeutic strategy for NPC.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Head and Neck-Journal for the Sciences and Specialties of the Head and Neck 医学-耳鼻喉科学

CiteScore

7.00

自引率

6.90%

发文量

278

审稿时长

1.6 months

期刊介绍： Head & Neck is an international multidisciplinary publication of original contributions concerning the diagnosis and management of diseases of the head and neck. This area involves the overlapping interests and expertise of several surgical and medical specialties, including general surgery, neurosurgery, otolaryngology, plastic surgery, oral surgery, dermatology, ophthalmology, pathology, radiotherapy, medical oncology, and the corresponding basic sciences.